{"organizations": [], "uuid": "f34bd82ba674c7c68eb0a1e6e94485459242df7f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/22/globe-newswire-chimerix-to-announce-fourth-quarter-and-full-year-2017-financial-results-on-march-1-2018.html", "country": "US", "domain_rank": 767, "title": "Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T16:00:00.000+02:00", "replies_count": 0, "uuid": "f34bd82ba674c7c68eb0a1e6e94485459242df7f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/22/globe-newswire-chimerix-to-announce-fourth-quarter-and-full-year-2017-financial-results-on-march-1-2018.html", "ord_in_thread": 0, "title": "Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018", "locations": [], "entities": {"persons": [{"name": "chimerix", "sentiment": "none"}, {"name": "chimerix chimerix", "sentiment": "none"}], "locations": [{"name": "durham", "sentiment": "none"}, {"name": "n.c.", "sentiment": "none"}], "organizations": [{"name": "chimerix, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "DURHAM, N.C., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Thursday, March 1, 2018 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2017, and to provide a business overview.\nTo access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1153769. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com . An archived webcast will be available on the Chimerix website approximately two hours after the event.\nAbout Chimerix\nChimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and Compound Library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus to enter clinical testing. For further information, please visit Chimerix's website, www.chimerix.com .\nCONTACT:\nInvestor Relations:\nMichelle LaSpaluto\n919-972-7115\nir@chimerix.com\nor\nWill O’Connor\nStern Investor Relations\nWill@sternir.com\n212-362-1200\nMedia:\nBecky Vonsiatsky\nW2O Group\nbvonsiatsky@w2ogroup.com\n413-478-2003\nSource:Chimerix, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/9b5bc625-104d-4a8b-9efc-877699d633d4", "https://www.globenewswire.com/Tracker?data=U3uX8LkjtP7p9hbIyQh20ct6eeeHBu3_qgIDgXMbaMOALc1cBTKHet2XAHKl0B8EDSNnz0G6rcSGQQl8Dq0mZ2m_iU0pfMWQWhShsO434l0=", "https://www.globenewswire.com/Tracker?data=JXzLwWGRsLXXVPfi6Q6M7rioDcM1lc6f3xBMDj9nNIcPKfe2KBxs9nH132leXvVf", "https://www.globenewswire.com/Tracker?data=jSrvh5hoEw5PVVZNX9HBYusCIjpK7jqCEm7B_6fYuTW8RTHGCG3cP0MkjqVaOPee6Ms2ku5y2B6D_EIdppRiow==", "https://www.globenewswire.com/Tracker?data=0qKIlT6qI87pdg6gCPYiMmJPZR6gQZMy9rdoyF_tvRWwzm2f_BgEkLhGnW51oyXc", "https://www.globenewswire.com/Tracker?data=17TTlv7dNQ_k2OUJc6L6-Jl4DurWVyM-ajbxARrNE1MzNO7h197qB7Gsk8zNc_s4_QijqRVsGOdQZ9imp9bV5Q==", "https://www.globenewswire.com/Tracker?data=4979BmasXBp4v20TzV-orpUijqFsTpdWk6rqP1Iiu94mR2m9GvaCQLN8KuVqkb8t-tpaLY_ooEkG3cOI0WF_odaVZa-K8MBVToQ0VjcpvKWtghXhmS0mb5bhey_i1VcjNIr3wOBEsuzx4FQRDag0FGLmm6-o_3ljYizP7vYWKh2X8WL4dPzAHr6Q3UrH_P230JsdiCQtL7vL7Cjhce46oHSF1UZym8-8egF7kUgFm-g=", "https://www.globenewswire.com/Tracker?data=oVaE5QiREMu7NMfDKDeVQA4svhDSSvWo9pEcRccdK01pLwz9Cj2lzlG6okyw9anpp-gxlSZaV5-Pp0yfhgyduQ==", "https://www.globenewswire.com/Tracker?data=4979BmasXBp4v20TzV-ortfJsllSZrV4uqb-EuVU8rf-9iXyFL76XRq6tDzI4vQ-QEn7-s-pMh7PHcnvDxhvKQ=="], "published": "2018-02-22T16:00:00.000+02:00", "crawled": "2018-02-22T17:53:51.183+02:00", "highlightTitle": ""}